Blood Proteins Patents (Class 435/69.6)
-
Publication number: 20150010542Abstract: The present invention provides methods and compositions for modulating Toso activity and treating diseases and disorders in which Toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a Toso protein or to a ligand of a Toso protein.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Tak W. Mak, Xiuqiu Lai, Michael W. Tusche
-
Publication number: 20150005475Abstract: The disclosure provides a method of reducing aggregates in a preparation of monoclonal antibody by modifying at least three parameters in the bioreactor culture process.Type: ApplicationFiled: February 1, 2013Publication date: January 1, 2015Applicant: MEDIMMUNE LIMITEDInventors: Justyna Kucia, Marcel Kuiper, Richard Tran, David Gruber
-
Publication number: 20150004177Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: June 27, 2014Publication date: January 1, 2015Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
-
Publication number: 20150004618Abstract: The invention relates to a method for linking at least two target nucleic acid molecules from a single biological compartment, comprising the steps of isolating a fraction from a sample, wherein the fraction comprises the compartment comprising at least two nucleic acid molecules; diluting said fraction and aliquoting the dilution in multiple separate reaction vessels such that each reaction vessel comprises preferably one compartment, or encapsulating said compartment in emulsion droplets such that each droplet comprises preferably one compartment; linking said at least two target nucleic acid molecules, preferably by overlap extension PCR. The method may be employed in the analysis of mutations present in a single cell and in the production of antibodies which are present in a single hybridoma.Type: ApplicationFiled: February 6, 2013Publication date: January 1, 2015Applicant: MAX-PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Hans-Joerg Warnatz, Joern Gloekler, Hans Lehrach
-
Publication number: 20150004155Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.Type: ApplicationFiled: November 16, 2012Publication date: January 1, 2015Applicant: AIMM THERAPEUTICS B.V.Inventors: Tim Beaumont, Etsuko Yasuda
-
Publication number: 20140377272Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Applicant: ROCHE GLYCART AGInventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
-
Publication number: 20140377805Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: May 29, 2014Publication date: December 25, 2014Applicant: AbbVie Inc.Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
-
Publication number: 20140377804Abstract: A filamentous fungal cell having reduced UDP-galactofuranose is provided. The fungal cell may, in certain embodiments, contain a nuclear genome comprising an inactivated UDP-galactopyranose mutase (UDP-galp mutase) gene and a recombinant nucleic acid for expression of a protein. Also provided are methods of producing a protein using the subject fungal cell, as well as methods of producing the subject fungal cell.Type: ApplicationFiled: April 11, 2014Publication date: December 25, 2014Applicant: DANISCO US INC.Inventors: Michael Ward, Wouter Vervecken, Roland Contreras
-
Publication number: 20140377803Abstract: The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.Type: ApplicationFiled: May 14, 2012Publication date: December 25, 2014Applicant: PROBIOGEN AGInventors: Volker Sandig, Karsten Winkler, Henning Von Horsten, Thomas Rose
-
Publication number: 20140378663Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.Type: ApplicationFiled: June 25, 2012Publication date: December 25, 2014Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIESInventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
-
Publication number: 20140377806Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
-
Publication number: 20140377288Abstract: The present invention provides compositions and methods for treating a cancer associated with elevated expression and/or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5. In some embodiments, the present invention provides compositions and methods for identifying elevated expression or activity of receptor tyrosine kinases (e.g., Eph receptors), such as EphA5.Type: ApplicationFiled: September 14, 2012Publication date: December 25, 2014Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Fernanda I. Staquicini, Renata Pasqualini, Wadih Arap
-
Publication number: 20140377273Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Applicant: ROCHE GLYCART AGInventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
-
Publication number: 20140377271Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.Type: ApplicationFiled: April 18, 2014Publication date: December 25, 2014Applicant: Dr. Rentschler Holding GmbH & Co. KGInventors: Richard DODEL, Michael BACHER, Daniela BESONG AGBO, Sascha HAGEMANN, Monika BALZER-GELDSETZER, Bernd REHBERGER, Renee WEBER
-
Publication number: 20140378664Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Hye young SUH, Jae II Lee, Su-Jeong Hwang
-
Publication number: 20140377270Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: March 12, 2014Publication date: December 25, 2014Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Publication number: 20140377279Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.Type: ApplicationFiled: September 13, 2013Publication date: December 25, 2014Applicant: MedImmune LimitedInventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
-
Publication number: 20140377280Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.Type: ApplicationFiled: December 10, 2012Publication date: December 25, 2014Inventors: Jeffrey V. Ravetch, Andrew Pincetic
-
Publication number: 20140377253Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.Type: ApplicationFiled: March 14, 2014Publication date: December 25, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
-
Publication number: 20140377256Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.Type: ApplicationFiled: May 23, 2014Publication date: December 25, 2014Applicant: Xencor, Inc.Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
-
Publication number: 20140380515Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: ApplicationFiled: July 24, 2014Publication date: December 25, 2014Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
-
Publication number: 20140377255Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: May 13, 2014Publication date: December 25, 2014Applicant: PFIZER INCInventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20140377802Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.Type: ApplicationFiled: July 3, 2014Publication date: December 25, 2014Inventors: James M. CREGG, Ilya I. TOLSTORUKOV
-
Publication number: 20140377265Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: ApplicationFiled: July 22, 2014Publication date: December 25, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
-
Publication number: 20140371160Abstract: A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t1/2) and the area under blood drug concentration vs. time curve (AUC) are remarkably increased by adding an N-glycosylation site in animal cells through amino acid mutation between 1st and 25th positions of the N-terminus of alpha-1 antitrypsin. Therefore, the alpha-1 antitrypsin variant can be useful in preventing or treating alpha-1 antitrypsin deficiency.Type: ApplicationFiled: August 13, 2012Publication date: December 18, 2014Applicant: ALTEOGEN, INCInventors: Soon Jae Park, Hye-Shin Chung, Sang Mee Lee, Ji-Sun Kim
-
Publication number: 20140371429Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.Type: ApplicationFiled: April 10, 2014Publication date: December 18, 2014Applicant: GENENTECH, INC.Inventors: Matthew Marrichi, Dorothea E. Reilly
-
Publication number: 20140370020Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH 1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.Type: ApplicationFiled: October 31, 2012Publication date: December 18, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Meiri Kawazoe, Naoka Hironiwa, Tomoyuki Igawa
-
Publication number: 20140370547Abstract: Herein is reported an expression vector comprising—an antibody light chain expression cassette,—an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5? to 3? sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.Type: ApplicationFiled: December 19, 2012Publication date: December 18, 2014Inventors: Peter Michael Huelsmann, Hendrik Knoetgen
-
Publication number: 20140370548Abstract: Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3.Type: ApplicationFiled: September 2, 2014Publication date: December 18, 2014Inventors: Bruce KEYT, Lawrence M. KAUVAR, Ellen J. COLLARINI, Orit FOORD, Gizette SPERINDE, Marjan FATHOLAHI, Hung NGUYEN
-
Publication number: 20140369994Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: William N. Drohan, Michael J. Griffith
-
Publication number: 20140370019Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: April 1, 2014Publication date: December 18, 2014Applicant: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
-
Publication number: 20140370013Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.Type: ApplicationFiled: January 14, 2014Publication date: December 18, 2014Applicant: Xencor, Inc.Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
-
Publication number: 20140370008Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.Type: ApplicationFiled: December 14, 2012Publication date: December 18, 2014Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20140370036Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.Type: ApplicationFiled: August 21, 2014Publication date: December 18, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventor: Leland SHAPIRO
-
Patent number: 8911726Abstract: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.Type: GrantFiled: September 22, 2005Date of Patent: December 16, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Nobuaki Takahashi, Hideaki Yoshida
-
Patent number: 8911964Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: March 26, 2014Date of Patent: December 16, 2014Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
-
Publication number: 20140363429Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.Type: ApplicationFiled: November 20, 2012Publication date: December 11, 2014Applicant: MedImmune LLCInventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
-
Publication number: 20140363434Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: December 11, 2014Applicant: COMPLIX NVInventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
-
Publication number: 20140363445Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.Type: ApplicationFiled: August 11, 2014Publication date: December 11, 2014Applicant: ZENYTH OPERATIONS PTY LTDInventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
-
Publication number: 20140363426Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.Type: ApplicationFiled: March 17, 2014Publication date: December 11, 2014Inventors: GREGORY MOORE, MATTHEW BERNETT, RUMANA RASHID, JOHN DESJARLAIS
-
Publication number: 20140363428Abstract: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug aType: ApplicationFiled: September 28, 2012Publication date: December 11, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Futa Mimoto, Taichi Kuramochi
-
Publication number: 20140363845Abstract: The disclosure provides compositions and methods for high density cell culture and banking of cholesterol auxotrophic cells.Type: ApplicationFiled: May 15, 2014Publication date: December 11, 2014Applicant: Biogen Idec MA Inc.Inventors: Marty Sinacore, Yiwen Tao, Thomas Ryll, Helena Yusuf-Makagiansar
-
Publication number: 20140363422Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: January 2, 2013Publication date: December 11, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
-
Publication number: 20140363438Abstract: The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1? and neuregulin 1? isoforms.Type: ApplicationFiled: August 16, 2012Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Erica Jackson, Gabriele Schaefer, Yan Wu
-
Publication number: 20140363430Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: September 25, 2013Publication date: December 11, 2014Applicant: CYTOMX THERAPEUTICS, INC.Inventors: James William West, Jason Gary Sagert, Daniel Robert Hostetter, Stephen James Moore, Margaret Thy Luu Nguyen, Olga Vasiljeva, Jeanne Grace Flandez
-
Patent number: 8906680Abstract: The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: GrantFiled: December 21, 2007Date of Patent: December 9, 2014Assignee: Ablynx N.V.Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
-
Patent number: 8906646Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: March 26, 2014Date of Patent: December 9, 2014Assignee: AbbVie Inc.Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
-
Patent number: 8907072Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: February 5, 2013Date of Patent: December 9, 2014Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20140356375Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 22, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen